You think Algernon actually has competition? Yeah, we see how Algernon stacks up against companies that are winners like Bellus Health ($850M market cap/Chronic Cough) or GH Research ($1B market cap/one trick pony/ DMT). Those are real companies getting real value for shareholders. The type of "competition" Algernon wants to model is Xortx ($25M market cap/Chronic Kidney Disease). Xortx is a recently uplisted penny stock (sub $2 per share) trading on Nasdaq. Christopher Moreau recently hired their former CEO to "advise" on business strategy - smh.
Algernon is not competing with ANY company chasing after Cancer or any other disease given Algernon's foot dragging timelines to data readouts. I would have thought you were aware that there's more than one type of Cancer. Cancer competition? Also, you seem to want to understand a capital raise is coming with an uplist or not. My point has always remained the same here. I just keep explaining it to you over and over again. A capital raise is coming BEFORE any of the clinical trials are completed. They need money now - period.
(I'll reserve this space to say it all again a billion more times)
News 
Market Data 
Discover 
